Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Progyny
(NASDAQ:PGNY)
Intraday
$32.80
0.92
[2.89%]
After-Hours
$32.80
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$32.80
0.92
[2.89%]
At close: Apr 19
$32.80
0
[0.00%]
After Hours: 4:28PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Progyny Stock (NASDAQ:PGNY)
Progyny Stock (NASDAQ: PGNY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 17, 2024
Truist Securities Reiterates Buy on Progyny, Maintains $46 Price Target
Benzinga Newsdesk
-
2 days ago
Wednesday, February 28, 2024
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Feb 28, 2024, 2:02PM
Cantor Fitzgerald Reiterates Overweight on Progyny, Maintains $48 Price Target
Benzinga Newsdesk
-
Feb 28, 2024, 11:14AM
Truist Securities Maintains Buy on Progyny, Lowers Price Target to $46
Benzinga Newsdesk
-
Feb 28, 2024, 10:21AM
Progyny shares are trading lower after the company reported mixed Q4 financial results.
Benzinga Newsdesk
-
Feb 28, 2024, 8:27AM
Keybanc Maintains Overweight on Progyny, Lowers Price Target to $43
Benzinga Newsdesk
-
Feb 28, 2024, 5:09AM
Tuesday, February 27, 2024
Progyny Expects Q1 Revenue Of $285M-$292M (Est $312.64M); Adjusted EPS Of $0.33-$0.35 (Est $0.18)
Benzinga Newsdesk
-
Feb 27, 2024, 5:31PM
Progyny Expects 2024 Revenue Of $1.285B-$1.315B (Est $1.311B); Adjusted EPS Of $1.54-$1.59 (Est $0.70)
Benzinga Newsdesk
-
Feb 27, 2024, 5:30PM
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Feb 27, 2024, 4:31PM
Progyny shares are trading lower after the company reported mixed Q4 financial results.
Benzinga Newsdesk
-
Feb 27, 2024, 4:17PM
Progyny: Q4 Earnings Insights
Benzinga Insights
-
Feb 27, 2024, 4:15PM
Progyny Q4 2023 GAAP EPS $0.13 Beats $0.10 Estimate, Sales $269.94M Miss $273.66M Estimate
Benzinga Newsdesk
-
Feb 27, 2024, 4:14PM
Earnings Scheduled For February 27, 2024
Benzinga Insights
-
Feb 27, 2024, 5:01AM
Monday, February 26, 2024
Leerink Partners Initiates Coverage On Progyny with Outperform Rating, Announces Price Target of $49
Benzinga Newsdesk
-
Feb 26, 2024, 9:15AM
Friday, February 23, 2024
Presidential Candidate Donald Trump Says He Supports Availability Of In Vitro Fertilization Treatments And Calls On Alabama Legislature To Find "Immediate Solution"
Benzinga Newsdesk
-
Feb 23, 2024, 2:27PM
Thursday, January 25, 2024
Affordable Care Act Enrollment Highest Since Inception: Obamacare Enrollment Witnesses 31% Jump in 2024
Vandana Singh
-
Jan 25, 2024, 9:44AM
Thursday, December 14, 2023
Progyny Director Trades Company's Stock
Benzinga Insights
-
Dec 14, 2023, 10:03AM
Wednesday, November 08, 2023
Truist Securities Maintains Buy on Progyny, Lowers Price Target to $47
Benzinga Newsdesk
-
Nov 8, 2023, 10:21AM
Analyst Ratings for Progyny
Benzinga Insights
-
Nov 8, 2023, 8:00AM
Keybanc Maintains Overweight on Progyny, Lowers Price Target to $45
Benzinga Newsdesk
-
Nov 8, 2023, 7:45AM
Tuesday, November 07, 2023
Progyny Sees Q4 2023 Revenue $268.3M-$276M Vs $274.23M Est
Benzinga Newsdesk
-
Nov 7, 2023, 4:42PM
Progyny Sees FY23 Revenue $1.087B-$1.095B Vs $1.08B Est
Benzinga Newsdesk
-
Nov 7, 2023, 4:41PM
Progyny Q3 2023 EPS $0.16 Beats $0.12 Estimate, Revenue $280.891M Beats $271.189M Estimate
Benzinga Newsdesk
-
Nov 7, 2023, 4:39PM
Earnings Scheduled For November 7, 2023
Benzinga Insights
-
Nov 7, 2023, 6:34AM
Monday, October 09, 2023
JP Morgan Maintains Overweight on Progyny, Lowers Price Target to $57
Benzinga Newsdesk
-
Oct 9, 2023, 2:48PM
Wednesday, September 27, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Benzinga Insights
-
Sep 27, 2023, 11:00AM
The Latest Analyst Ratings for Progyny
Benzinga Insights
-
Sep 27, 2023, 10:00AM
Canaccord Genuity Initiates Coverage On Progyny with Buy Rating, Announces Price Target of $46
Benzinga Newsdesk
-
Sep 27, 2023, 5:00AM
Tuesday, September 26, 2023
Watching Progyny; Hearing Traders Circulate Unconfirmed Newsletter Pick
Benzinga Newsdesk
-
Sep 26, 2023, 1:03PM
Thursday, September 14, 2023
Cantor Fitzgerald Maintains Overweight on Progyny, Raises Price Target to $48
Benzinga Newsdesk
-
Sep 14, 2023, 9:13AM
Wednesday, September 13, 2023
Check Out What Whales Are Doing With PGNY
Benzinga Insights
-
Sep 13, 2023, 1:00PM
Friday, August 11, 2023
Truist Securities Maintains Buy on Progyny, Raises Price Target to $52
Benzinga Newsdesk
-
Aug 11, 2023, 11:43AM
Friday, August 04, 2023
Progyny shares are trading higher after the company reported better-than-expected Q2 results and issued strong guidance.
Benzinga Newsdesk
-
Aug 4, 2023, 12:20PM
Progyny Unveils Nationwide Access To Menopause Care
Happy Mohamed
-
Aug 4, 2023, 9:05AM
The Latest Analyst Ratings for Progyny
Benzinga Insights
-
Aug 4, 2023, 9:00AM
Keybanc Maintains Overweight on Progyny, Raises Price Target to $50
Benzinga Newsdesk
-
Aug 4, 2023, 6:08AM
Thursday, August 03, 2023
Progyny Sees FY23 EPS $0.5-$0.53 Vs $0.47 Est; Revenue $1.075B-$1.09B Vs $1.06B Est
Benzinga Newsdesk
-
Aug 3, 2023, 6:02PM
Progyny Sees Q3 EPS $0.09-$0.10 Vs $0.11 Est; Revenue $268M-$273M Vs $265.24M Est
Benzinga Newsdesk
-
Aug 3, 2023, 6:01PM
Progyny Q2 EPS $0.15 Beats $0.10 Estimate, Sales $279.37M Beat $261.91M Estimate
Benzinga Newsdesk
-
Aug 3, 2023, 4:14PM
Earnings Scheduled For August 3, 2023
Benzinga Insights
-
Aug 3, 2023, 6:59AM
Monday, May 22, 2023
5 Analysts Have This to Say About Progyny
Benzinga Insights
-
May 22, 2023, 1:02PM
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
Benzinga Insights
-
May 22, 2023, 11:00AM
Looking Into Progyny's Return On Capital Employed
Benzinga Insights
-
May 22, 2023, 10:47AM
BTIG Initiates Coverage On Progyny with Buy Rating, Announces Price Target of $50
Benzinga Newsdesk
-
May 22, 2023, 7:35AM
Wednesday, May 17, 2023
Progyny Chief Executive Officer Acquires 64,000 Shares After Exercising Company Stock Options
Benzinga Insights
-
May 17, 2023, 11:02AM
Monday, May 15, 2023
JP Morgan Maintains Overweight on Progyny, Lowers Price Target to $58
Benzinga Newsdesk
-
May 15, 2023, 9:40AM
Tuesday, May 09, 2023
Progyny shares are trading higher after the company reported better-than-expected Q1 results and issued strong guidance.
Benzinga Newsdesk
-
May 9, 2023, 11:36AM
B of A Securities Maintains Buy on Progyny, Raises Price Target to $50
Benzinga Newsdesk
-
May 9, 2023, 10:50AM
Cantor Fitzgerald Maintains Overweight on Progyny, Raises Price Target to $45
Benzinga Newsdesk
-
May 9, 2023, 7:26AM
Monday, May 08, 2023
Progyny Sees Q2 Revenue $260M-$265M Vs $253.35M Est., EPS $0.09-$0.10 Vs $0.08 Est.
Michael Horton
-
May 8, 2023, 4:06PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch